scispace - formally typeset
S

Seon-Won Kim

Researcher at Gyeongsang National University

Publications -  116
Citations -  4716

Seon-Won Kim is an academic researcher from Gyeongsang National University. The author has contributed to research in topics: Escherichia coli & Mevalonate pathway. The author has an hindex of 35, co-authored 109 publications receiving 4060 citations. Previous affiliations of Seon-Won Kim include University of California, Berkeley.

Papers
More filters
Journal ArticleDOI

Metabolic engineering of the nonmevalonate isopentenyl diphosphate synthesis pathway in Escherichia coli enhances lycopene production.

TL;DR: Given the low final densities of cells expressing dxs from IPTG-inducible promoters, the low lycopene production was probably due to the metabolic burden of plasmid maintenance and an excessive drain of central metabolic intermediates.
Journal ArticleDOI

Low-copy plasmids can perform as well as or better than high-copy plasmids for metabolic engineering of bacteria.

TL;DR: Low-copy plasmids may be useful in metabolic engineering applications, particularly when one or more of the substrates used in the recombinant pathway are required for normal cellular metabolism.
Journal ArticleDOI

Combinatorial expression of bacterial whole mevalonate pathway for the production of β-carotene in E. coli

TL;DR: The recombinant E. coli strains - MG1655, DH5alpha, S17-1, XL1-Blue and BL21 - the DH5 alpha was found to be the best beta-carotene producer and glycerol as the carbon source for beta- carotene production was foundto be superior to glucose, galactose, xylose and maltose.
Journal ArticleDOI

An update on microbial carotenoid production: application of recent metabolic engineering tools.

TL;DR: Recent progress made in metabolic engineering of non-carotenogenic microorganisms with particular focus on the potential of Escherichia coli for improved carotenoid productivity are described.
Journal ArticleDOI

Metabolic engineering of Escherichia coli for α-farnesene production.

TL;DR: The engineered E. coli strain was able to produce 380.0 mg/L of α-farnesene, which is an approximately 317-fold increase over the initial production of 1.2mg/L, and an additional increase was achieved by the protein fusion of FPP synthase and α- fernesene synthase.